SCY-078 Salt Forms for Solubility and Hygroscopicity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of SCY-078, a glucan synthase inhibitor, face challenges in achieving optimal kinetic solubility and hygroscopicity, which are crucial for effective intravenous formulations and solid dosage forms, particularly in treating fungal infections like Invasive Candidiasis and Invasive Aspergillosis.
Innovation Solution
The development of pharmaceutically acceptable salts and polymorphs of SCY-078, such as citrate, hippurate, mesylate, fumarate, and calcium salts, which exhibit enhanced kinetic solubility and controlled hygroscopicity, facilitating better formulation and stability for intravenous administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional formulations of SCY-078 are used, then the compound can be administered, but the kinetic solubility is insufficient for effective intravenous formulations
Solution Approach 1:
The patent applies parameter changes by converting SCY-078 from its freebase form into various salt forms (citrate, hippurate, mesylate, fumarate, calcium salts). This chemical parameter transformation fundamentally alters the solubility characteristics of the compound, enabling it to achieve the required kinetic solubility levels (e.g., ≥2 mg/mL at 4 hours in dextrose buffer at pH 5.5) necessary for effective intravenous formulations.
Solution Approach 2:
The patent creates composite material systems by forming salts of SCY-078 with various counterions. These composite structures (e.g., SCY-078 citrate, SCY-078 hippurate) combine the active pharmaceutical ingredient with salt-forming agents to produce materials with optimized solubility and dissolution properties while maintaining the therapeutic efficacy of the parent compound.
2Quantity of substance
If salts of SCY-078 are developed to improve solubility, then kinetic solubility increases, but control over hygroscopicity becomes critical for solid dosage form stability
Solution Approach 1:
The patent applies local quality by selecting specific salt forms of SCY-078 that exhibit particular hygroscopicity characteristics suited for different dosage form requirements. For example, certain salts like SCY-078 citrate and SCY-078 hippurate demonstrate controlled water sorption properties that make them particularly suitable for solid dosage forms, while other salts may be preferred for injectable formulations where hygroscopicity is less critical.
Solution Approach 2:
The patent utilizes parameter changes by systematically evaluating and selecting salt forms based on their hygroscopicity parameters. The disclosed salts exhibit water sorption of not greater than 7% at 25°C and 80% relative humidity, representing an optimized parameter range that balances solubility enhancement with stability requirements for solid dosage forms.
3Adaptability or versatility
If multiple salt forms and polymorphs are developed, then formulation options increase, but the complexity of preparation and characterization increases
Solution Approach 1:
The patent applies segmentation by dividing the development into distinct salt forms (citrate, hippurate, mesylate, fumarate, calcium salts) and polymorphic types (Type A, Type B, Type C, etc.). Each salt form and polymorph is characterized and prepared using specific methodologies, allowing the complex overall problem to be managed through systematic segmentation into manageable development modules with defined preparation protocols and characterization criteria.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
SCY-078 is a glucan synthase inhibitor with antimicrobial activity. Novel salts and polymorph forms of SCY-078 are disclosed herein. The disclosure also relates to pharmaceutical compositions, methods of use, and methods of preparing the novel salts and polymorphs of SCY-078 in particular the citrate salt thereof.